Imprivata and Modeus partner on fast and secure reauthentication and witness signing workflows for HS8

Imprivata®, the healthcare IT security company, is delighted to announce a partnership with Modeus, an Australian software company specialising in electronic controlled drug management platforms for the healthcare industry.

Imprivata services over 1700 clients globally and enables healthcare to access, communicate and transact patient information securely and conveniently. Modeus services over 4000 customers throughout the Australian healthcare industry with electronic controlled substance register platforms, covering hospital, retail pharmacy, veterinary, aged care, ambulance and other health related verticals. Modeus is also currently expanding product launches into international markets.

Modeus has recently developed HS8, an electronic controlled drug management platform specifically designed for hospitals, enabling paperless controlled drug administration in all areas of a hospital, including pharmacy, wards and theatres. Through HS8 integration with Imprivata Confirm ID™, a comprehensive identity and authentication workflow will enable all hospital users to confirm HS8 register entries via a via fingerprint or a card tap instead of either paper-based signing of the Drugs-of-Dependence DD book, or entering a username and password.

The partnership between the two companies provides fast and secure access to HS8, promoting efficiency, effectiveness and integration throughout the healthcare environment. When combined with Imprivata Confirm ID™ HS8 provides safeguards to help improve patient safety by incorporating witness signing and reauthentication across a range of receipt of stock orders, dispensing from pharmacy and administrative workflows.

Dr. Sean Kelly, Chief Medical Officer at Imprivata, commented; “Too often IT security practices can be a barrier to delivering care. At Imprivata we believe that if IT security doesn’t work for people, then it doesn’t work at all. Our partnership with Modeus reduces the time taken to reauthenticate and witness Schedule 8 workflows allowing more time for improvements in the quality-of-care. Digitising these workflows enables Imprivata and Modeus to provide a secure, audited trail of who did what, where, and when – witnessed by whom – as it relates to Schedule 8 medicines. The replacement of DD books (one of the last paper-based processes to be resolved) with Modeus HS8 integrated with Imprivata Confirm ID™ both digitises and optimises fast, secure records of access and witnessing of restricted Schedule 8 medicines.”

Carl Zufi, CEO of Modeus commented; "Some of the biggest goals for HS8 was to improve clinical workflow efficiency whilst maintaining a highly secure system that provides full accountability and transparency. Our partnership with Imprivata allows just that. By integrating HS8 with Imprivata’s Confirm ID solution, which includes support for tap card and fingerprint re-authentication, users will no longer be required to manually enter a username and password for each controlled drug register entry. In many cases, the integration can leverage or extend on the customer’s existing Imprivata infrastructure. The integration will also allow busy areas such as wards to run HS8 off a touchscreen without the need for a keyboard and mouse for most transactions. Together with Imprivata, we are looking forward to helping hospitals adopt the new technologies that will allow clinicians to spend less time on administration and more time caring for their patients"

About Imprivata
Imprivata®, the healthcare IT security company, provides healthcare organisations globally with a security and identity platform that delivers ubiquitous access, positive identity management, and multifactor authentication. Imprivata enables healthcare securely by establishing trust between people, technology, and information to address critical compliance and security challenges while improving productivity and the patient experience.

For more information please visit: